Conference Coverage

Chlamydia infections associated with more than a doubling of ovarian cancer risk

Publish date: March 16, 2018

 

FROM THE AACR ANNUAL MEETING


Neither cohort showed any significant association of ovarian cancer with any of the other antibodies, Dr. Trabert said.

The NCI Intramural Research Program supported the study. Dr. Trabert and her colleagues declared no conflicts of interest.

SOURCE: Trabert et al. Abstract 4942.

Pages

Recommended Reading

HIPEC shows survival benefit for advanced ovarian cancer
MDedge ObGyn
Approach to the asymptomatic adnexal mass: When to operate, refer, or observe
MDedge ObGyn
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge ObGyn
Letrozole promising as maintenance treatment for high-grade serous ovarian cancer
MDedge ObGyn
USPSTF: Routine screens for ovarian cancer not recommended
MDedge ObGyn
FDA approves new HPV assay
MDedge ObGyn
Telling her she has cancer: A patient-centered approach to breaking bad news
MDedge ObGyn
2018 Update on gynecologic cancer
MDedge ObGyn
Avelumab safety compares with other checkpoint inhibitors
MDedge ObGyn
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge ObGyn